Month: December 2020

AB „Panevėžio statybos trestas“ (PST) pasirašė sutartį dėl Kultūros paskirties pastato Respublikos g. 40, Panevėžyje rekonstravimo darbų. Pastato bendras plotas – 3746 kv. m. Sutarties kaina virš 9 mln. eurų. Darbus numatoma atlikti per 20 mėn.Daugiau informacijos:Generalinis direktoriusEgidijus UrbonasTel.: (8-45) 505 503

Lannion, December 2, 2020 – 7:45amLUMIBIRD secures €140m of Euro PP and bank financing TO SUPPORT ITS STRATEGIC AMBITIONSThe LUMIBIRD Group, the European leader for laser technologies, is announcing that it has set up €100m of bank financing and completed a €40m Euro PP social impact bond issue. With these financing facilities, the LUMIBIRD Group has increased its capacity for investment by over €100m and aims to double its revenues between 2020 and 2023. This target is based on organic growth for one third and external growth for two thirds.The LUMIBIRD Group is announcing today that it has set up €140m of financing based on a seven-year maturity with a view to securing continued growth around its already successful model that combines organic and external growth. LUMIBIRD aims to double its revenues between 2020 and 2023, with growth...

Lannion, le 02/12/2020 – 7h45LUMIBIRD Boucle 140 m€ de financement bancaire et euro pp pour soutenir ses ambitions stratégiquesLe Groupe LUMIBIRD, leader européen des technologies laser, annonce la mise en place d’un financement bancaire à hauteur de 100 M€ et l’émission d’un emprunt obligataire Euro PP à impact social de 40 M€. Le groupe LUMIBIRD dispose avec ces financements d’une capacité d’investissement accrue de plus de 100 M€ qui doit lui permettre de doubler son chiffre d’affaires entre 2020 et 2023. Cet objectif repose pour un tiers sur la croissance organique et pour deux tiers sur la croissance externe.Le Groupe LUMIBIRD annonce ce jour la mise en place d’un financement de 140 M€ pour une durée de 7 ans, dans le but de sécuriser la poursuite de sa croissance sur un modèle mixte déjà éprouvé de croissance organique et de croissance...

MARSEILLE, France, Dec. 02, 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2021 financial calendar:All financial reports are released before market open CET.All corporate information, such as the Company’s financial statements and corporate presentations, is available on https://investors.innate-pharma.com.About Innate Pharma:Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty...

Marseille, Dec. 02, 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2021 financial calendar:March 18, 2021:         Publication of 2020 financial statementsMay 11, 2021:            Publication of revenue for 1Q2021May 28, 2021:            Annual General Shareholders MeetingSeptember 15, 2021:   Publication of half year financial statementsNovember 16, 2021:    Publication of revenue for 3Q2021All financial reports are released before market open CET.All corporate information, such as the Company’s financial statements and corporate presentations, is available on https://investors.innate-pharma.com. About Innate Pharma:Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical...

Marseille, 02 déc. 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris : FR0010331421 – IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») publie aujourd’hui son calendrier financier pour l’année 2021 :18 mars 2021 : Publication des résultats annuels 2020.11 mai 2021 : Publication du chiffre d’affaires du premier trimestre 2021.28 mai 2021 : Assemblée générale annuelle.15 septembre 2021 : Publication des résultats semestriels 2021.16 novembre 2021 : Publication du chiffre d’affaires du troisième trimestre 2021.Tous les rapports financiers sont publiés avant l’ouverture du marché CET.Toute l’information « corporate » sur la Société, telle que ses états financiers et ses présentations aux investisseurs, est disponible sur son site internet à l’adresse : http://www.innate-pharma.com/fr/investisseurs.À propos d’Innate Pharma...

Basel, 2 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto™ (pralsetinib) for the treatment of adult and paediatric patients 12 years of age and older with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) who require systemic therapy, or with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). These indications were approved under the FDA’s accelerated approval programme based on data from the phase I/II ARROW study. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.“We are proud to partner with...

Highlights:The trial is being conducted on a 20-acre field plot in west central Saskatchewan1.6 tonnes per acres of EarthRenew’s GrowER product was applied to the plotThe demonstration trial is intended to measure improvements in crop yield, soil acidity, soil organic matter and farmer profitabilityTORONTO, Dec. 02, 2020 (GLOBE NEWSWIRE) — EarthRenew Inc. (CSE:ERTH) (“EarthRenew” or the “Company”) is pleased to announce that it has started a long-term soil health demonstration trial with an agronomist at a farming operation in west central Saskatchewan in the “dark brown soil zone”. Soils in the dark brown zone are part of the cooler, wetter mixed grassland ecoregion and have a higher amount of Soil Organic Matter content, darker soil color and thicker soil development.The purpose of the field trial is to demonstrate the combined...

VANCOUVER, British Columbia, Dec. 02, 2020 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sector, is pleased to provide an introduction to Dr. Alexander MacGregor, a key scientific advisor to the Company.Pure Extracts and Dr. MacGregor are collaborating on the development of CBD infused mushroom wellness products and are researching the optimum extraction methodologies for psilocybin in order to prepare the Company to enter the psychedelic mushroom extraction space.Dr. MacGregor is the Dean of Faculty, distinguished Professor of Biopharmaceutics and current President of the Toronto Institute of Pharmaceutical Technology (TIPT®) – North America’s premier post-graduate...

SHENZHEN, China, Dec. 01, 2020 (GLOBE NEWSWIRE) — Meten EdtechX Education Group Ltd. (NASDAQ: METX) (“Meten EdtechX” or the “Company”), a leading omnichannel English language training (“ELT”) service provider in China, announces that its board of directors (the “Board”) had considered and approved the following items:The acquisition (the “Likeshuo Management Investment”) of 15% of newly issued shares of LIKESHUO EDUCATION (HONG KONG) LIMITED (“Likeshuo HK”) by certain senior members of the management of the Likeshuo online business and the reservation (the “Likeshuo ESOP Reservation”) of 5% of shares of Likeshuo HK for future share incentive awards. The consideration in respect of the Likeshuo Management Investment and Likeshuo ESOP Reservation consists of (i) RMB20.0 million cash consideration payable from the relevant Likeshuo...